miR-361-3p inhibitor

**miR-361-3p inhibitor** is a preclinical oligonucleotide-based RNA therapy directed against microRNA-361-3p for the treatment of breast cancer, including endocrine-responsive and endocrine-resistant disease. Based on the provided research context, the agent inhibits the oncogenic activity of miR-361-3p, a microRNA reported to be overexpressed in breast cancer tissues and associated with worse overall survival. In breast cancer cell models, miR-361-3p inhibition reduced proliferation and increased apoptosis, with activity observed in drug-responsive, aromatase inhibitor-resistant, and antiestrogen-resistant cells. The reported downstream biology includes modulation of FANCA and activation of p53-mediated G1 cell-cycle arrest, and synergy has been described in combination with olaparib. No proprietary product name, sponsoring company, manufacturer, or clinical-stage program was identified from the provided information.

Other names

miR-361-3p inhibitormiR361-3p inhibitormiR 361-3p inhibitormicroRNA-361-3p inhibitormicroRNA361-3p inhibitormicroRNA 361-3p inhibitor